Lilly to Acquire Merida Biosciences for Up to $2.875B

Lilly is buying Merida Biosciences at the first moment the platform has something harder than elegant biology: an initial signal in people. Eli Lilly and Company has agreed to acquire Merida Biosciences for up to $2.875B in cash, including an undisclosed upfront payment and contingent milestone payments. The companies announced the definitive agreement on August 31, 2026 and expect it to close in Q4 2026, subject to customary conditions and regulatory approvals.

The transaction moves Merida’s precision-immunology platform into one of the world’s largest drug-development organizations while its lead program remains in Phase 1. Lilly is buying an early clinical signal, a team built around pathogenic-antibody biology, and a platform designed to remove disease-causing antibodies without broadly suppressing normal immune function.

That distinction is the strategic center of the deal. Many autoimmune treatments control disease by dampening wider parts of the immune system, while Merida is trying to isolate the antibodies causing a specific condition and leave protective immunity intact. The science is early, but Lilly has seen enough to put a milestone-bearing acquisition structure behind it.

What Lilly Is Buying

The acquisition agreement values Merida at up to $2.875B in cash, but the headline number is not a guaranteed closing payment. Lilly disclosed that the total includes both an upfront payment and contingent milestones, without giving the split, milestone schedule, or exact conditions tied to the remaining consideration.

That structure lets Lilly secure the company and platform while leaving part of the maximum price dependent on future events. It also preserves the correct capital accounting for an early-stage biotechnology deal: the upfront amount is unknown, the milestone value is conditional, and the transaction has not yet closed.

Lilly said the transaction remains subject to regulatory approvals and other customary closing conditions. The company expects a Q4 2026 close, after which it will determine the accounting treatment and reflect the acquisition in its financial results and guidance.

How Merida’s Platform Works

Merida engineers Fc-based biotherapeutics to recognize selected pathogenic antibodies. According to the company’s science platform, the molecules are designed to bind those antibodies, direct them toward specialized liver cells for degradation, and inhibit the B cells that produce them through FcγRIIB signaling.

The commercial and clinical idea is selectivity. Instead of weakening immune activity across a broad system, a Merida therapy would target a defined disease driver while preserving protective antibodies and normal immune function. That promise still needs to survive larger and longer trials, but it gives Lilly a mechanism that could support more than one drug candidate.

The platform currently reaches across Graves’ disease, IgE-mediated allergic diseases, and primary membranous nephropathy. Merida says its discovery engine could address more than two dozen conditions caused by pathogenic antibodies, though that breadth remains a company development ambition rather than an approved product portfolio.

MER511 and the First Human Evidence

MER511 is Merida’s lead program and the first clinical test of the platform. The NEXUS Phase 1 study is evaluating single and multiple doses in adults with Graves’ disease, an autoimmune condition in which pathogenic antibodies stimulate the thyroid and drive excess hormone production.

Lilly said initial Phase 1 data showed robust reductions in thyroid-stimulating antibodies with a favorable initial safety profile. Those findings are preliminary and company-reported; results were not posted on the ClinicalTrials.gov record when this article was researched. They are meaningful because they offer an early human signal for the mechanism, not because they settle efficacy, durability, dose selection, or approval.

The acquisition also brings preclinical depth. Merida’s pipeline lists MER769 in IND-enabling development for IgE-mediated allergic diseases, including food allergy, asthma, and chronic spontaneous urticaria. MER683 is in IND-enabling development for primary membranous nephropathy, an autoimmune kidney disease.

The Company Behind the Platform

Third Rock Ventures seeded Merida in 2022 while founder and CSO Dario Gutierrez was an entrepreneur-in-residence. Merida launched publicly in April 2025 with a $121M Series A co-led by Bain Capital Life Sciences, BVF Partners, and Third Rock Ventures, with GV and Perceptive Xontogeny Venture Funds participating.

Gutierrez led the scientific formation of the platform, and Adam Townsend became CEO in March 2025 as the company moved toward clinical execution. Merida is headquartered in Cambridge, Massachusetts, where its current leadership also includes COO Dodzie Sogah, CFO Allison Dorval, Chief People Officer Tara Reagan, and SVP of Process and Product Development Michael Naill.

The speed from public launch to acquisition is notable but needs the right frame. Lilly is not buying a newly invented idea from a one-year-old press release; it is buying work seeded in 2022, financed for clinical development in 2025, and advanced far enough to generate an initial Phase 1 signal by the time of the transaction.

Why the Deal Matters for Lilly

Lilly enters the acquisition from a position of unusual scale. The company reported $65.179B in 2025 revenue and has been using both internal research and external acquisitions to expand its pipeline across cardiometabolic health, immunology, neuroscience, oncology, and genetic medicine.

Merida adds a precision-degradation platform to Lilly’s immunology capabilities. Francisco Ramírez-Valle, Lilly’s SVP for immunology research and early clinical development, described the opportunity as selectively eliminating the autoantibodies causing Graves’ disease and thyroid eye disease while preserving normal immune function, with possible applications across other antibody-driven diseases.

For Merida, Lilly supplies clinical-development resources, regulatory experience, manufacturing capacity, and a global commercial organization. None of those assets can substitute for convincing trial data, but they can determine how quickly a platform is tested across indications and whether a promising mechanism becomes a reproducible development engine.

The Market Signal

The acquisition shows how strategic buyers may value platform repeatability before late-stage validation. A single Phase 1 asset would make this a large early clinical transaction; a method that can be engineered against multiple pathogenic antibodies gives Lilly a broader reason to accept that timing.

The milestone component also tells the market where uncertainty lives. Lilly is securing ownership now while reserving part of the maximum consideration for development progress that has not been disclosed in detail. Investors and operators should read the $2.875B figure as a ceiling tied to an early platform opportunity, not as evidence that clinical risk has disappeared.

Merida now enters a larger system with the same unforgiving scientific question it carried as an independent company: can selective pathogenic-antibody removal produce meaningful, durable benefit without giving away the immune protection patients still need? Lilly has bought the right to pursue that answer across more programs. The value will be written in the trial data that follow.